Gn-RH agonist therapy is widely used for treatment of endometriosis. However, it is well known that there are some side effects due to too much suppress of plasma sex steroid hormone levels. The decrease of the BMD (bone mineral density) is a serious side effect, and the BMD values are decreasing significantly even in the short period during Gn-RH agonist therapy. In this review, the author shows the effect of bisphosphonate administration on the prevention of the bone loss during Gn-RH agonist therapy for the endometriosis. By the administration of EP (estrogen-progestogen) preparations, the decreasing of the BMD can prevent (so called add-back therapy), however, there are some patients who could not be administrated these drugs because of their previous diseases. Bisphosphonate administration is much effective for the prevention of the bone loss compared with EP preparations. From these results, it is concluded that bisphosphonate administration has a beneficial effect for the prevention of the bone loss during Gn-RH agonist treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Weighing up GnRH agonist therapy for endometriosis: outcomes and the treatment paradigm.
Expert Opin Pharmacother
January 2025
Obstetrics and Gynecology Department Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Introduction: Endometriosis is a chronic inflammatory estrogen-dependent disease affecting 10% of women worldwide leading to chronic pelvic pain and infertility which may be treated clinically or surgically.
Areas Covered: Current literaure was reviewed using the keywords 'gonadotropin releasing hormone agonists (GnRHa),' 'endometriosis,' 'infertility' and 'chronic pelvic pain.' Relevant papers prioritizing randomized controlled clinical trials (RCT), systematic reviews, meta-analyses, as well as international guidelines were evaluated.
GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.
Pharmaceuticals (Basel)
December 2024
College of Pharmacy, University of Illinois, Chicago, IL 60612, USA.
Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are a substantial therapeutic development, providing fast and reversible suppression of gonadotropins by directly blocking GnRH-R. Unlike typical GnRH agonists, these antagonists prevent the early hormonal flare, have a faster onset of action, and have a lower risk of cardiovascular problems.
View Article and Find Full Text PDFAggressive angiomyxoma of the vagina: A case report and literature review.
Medicine (Baltimore)
January 2025
Department of Internal Medicine, Division of Hematology and Oncology, Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Rationale: Aggressive angiomyxoma (AAM) is an exceptionally rare mesenchymal tumor that predominantly manifests in the female genital organs during the reproductive age. Its rarity alone makes it a fascinating subject for study. The diagnosis of AAM necessitates differentiation from other benign or mesenchymal tumors and can be confirmed through immunohistochemistry (IHC) staining.
View Article and Find Full Text PDFSPATIAL MEMORY RECOVERY IN AGED MALE RATS TREATED WITH LEUPROLIDE ACETATE, A GNRH AGONIST.
Acta Endocrinol (Buchar)
January 2025
Universidad Autónoma de Aguascalientes, Centro de Ciencias Básicas, Department of Physiology and Pharmacology.
Context: Studies indicate a decrease in spatial memory across species as they age. Moreover, consistent administration of Gonadotropin-releasing hormone (GnRH) improves learning abilities in older rats that have undergone gonadectomy.
Objective: The aim of this study was to investigate the effects of the GnRH agonist, leuprolide acetate (LA) on spatial memory in aged intact male rats and the expression of proteins associated with hippocampal plasticity.
Triggering final follicular maturation for IVF cycles.
Reprod Biol Endocrinol
January 2025
Infertility and IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), Ramat Gan, 52621, Israel.
As part of a conventional controlled ovarian hyperstimulation (COH) regimen, final follicular maturation is usually triggered by a single bolus dose of human chorionic gonadotropin (hCG). COH, which combines GnRH antagonist co-treatment with GnRH agonist(GnRHa) trigger, is often used in attempts to eliminate severe early ovarian hyperstimulation syndrome and to improve oocyte/embryo yield and quality. Recently, the combination of GnRHa, with hCG trigger has also been implemented into clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!